<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 20:07:36 -0700</creation_date>
  <update_date>2013-01-15 20:07:36 -0700</update_date>
  <accession>HMDBP08201</accession>
  <secondary_accessions>
    <accession>13912</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>GABA(A) receptor subunit alpha-4</synonym>
  </synonyms>
  <gene_name>GABRA4</gene_name>
  <general_function>Involved in ion transport</general_function>
  <specific_function>GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00492</accession>
      <name>Chlorine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00112</accession>
      <name>Gamma-Aminobutyric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14332</accession>
      <name>Lorazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14335</accession>
      <name>Ethchlorvynol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14376</accession>
      <name>Temazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14382</accession>
      <name>Butabarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14386</accession>
      <name>Butalbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14451</accession>
      <name>Talbutal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14457</accession>
      <name>Pentobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14493</accession>
      <name>Clobazam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14515</accession>
      <name>Meprobamate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13943</accession>
      <name>Alpha-hydroxyalprazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14562</accession>
      <name>Secobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14606</accession>
      <name>Metharbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14618</accession>
      <name>Chlordiazepoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14737</accession>
      <name>Thiopental</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14766</accession>
      <name>Clorazepate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14821</accession>
      <name>Midazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14828</accession>
      <name>Flurazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14932</accession>
      <name>Primidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14980</accession>
      <name>Oxazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14987</accession>
      <name>Methylphenobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15034</accession>
      <name>Triazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15201</accession>
      <name>Clonazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15440</accession>
      <name>Amobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15441</accession>
      <name>Aprobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15442</accession>
      <name>Butethal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15443</accession>
      <name>Heptabarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13940</accession>
      <name>3'-Hydroxyhexobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15510</accession>
      <name>Flunitrazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15511</accession>
      <name>Bromazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15534</accession>
      <name>Nitrazepam</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>ligand-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>extracellular ligand-gated ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>substrate-specific transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion channel activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>gaba receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>gaba-a receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>g-protein coupled receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>gamma-aminobutyric acid signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>anion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>inorganic anion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>chloride transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>ion transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>postsynaptic membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell junction</subcellular_location>
    <subcellular_location>synapse</subcellular_location>
    <subcellular_location>postsynaptic cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:4</chromosome_location>
    <locus>4p12</locus>
    <gene_sequence>&gt;1665 bp
ATGGTTTCTGCCAAGAAGGTACCCGCGATCGCTCTGTCCGCCGGGGTCAGTTTCGCCCTC
CTGCGCTTCCTGTGCCTGGCGGTTTGTTTAAACGAATCCCCAGGACAGAACCAAAAGGAG
GAGAAATTGTGCACAGAAAATTTCACCCGCATCCTGGACAGTTTGCTCGATGGTTATGAC
AACAGGCTGCGTCCTGGATTTGGGGGTCCTGTTACAGAAGTGAAAACTGACATATATGTC
ACCAGCTTTGGACCTGTTTCTGATGTTGAAATGGAATACACAATGGATGTGTTCTTCAGG
CAGACATGGATTGACAAAAGATTAAAATATGACGGCCCCATTGAAATTTTGAGATTGAAC
AATATGATGGTAACGAAAGTGTGGACCCCTGATACTTTCTTCAGGAATGGAAAGAAATCT
GTCTCACATAATATGACAGCTCCAAATAAGCTTTTTAGAATTATGAGAAATGGTACTATT
TTATACACAATGAGACTCACCATAAGTGCGGAGTGTCCCATGAGATTGGTGGATTTTCCC
ATGGATGGTCATGCATGCCCTTTGAAATTCGGGAGTTATGCCTATCCAAAGAGTGAGATG
ATCTATACCTGGACAAAAGGTCCTGAGAAATCAGTTGAAGTTCCGAAGGAGTCTTCCAGC
TTAGTTCAATATGATTTGATTGGGCAAACCGTATCAAGTGAAACCATCAAATCAATTACG
GGTGAATATATTGTTATGACGGTTTACTTCCACCTCAGACGGAAGATGGGTTATTTTATG
ATTCAGACCTATATTCCGTGCATTATGACAGTGATTCTTTCTCAAGTTTCATTTTGGATA
AATAAAGAATCAGTTCCCGCTAGGACTGTATTTGGAATAACAACTGTCCTCACCATGACC
ACACTAAGCATCAGTGCACGACATTCTTTGCCCAAAGTGTCCTATGCTACCGCCATGGAC
TGGTTCATAGCTGTCTGCTTTGCTTTTGTATTTTCGGCCCTTATCGAGTTTGCTGCTGTC
AACTATTTCACCAATATTCAAATGGAAAAAGCCAAAAGGAAGACATCAAAGCCCCCTCAG
GAAGTTCCCGCTGCTCCAGTGCAGAGAGAGAAGCATCCTGAAGCCCCTCTGCAGAATACA
AATGCCAATTTGAACATGAGAAAAAGAACAAATGCTTTGGTTCACTCTGAATCTGATGTT
GGCAACAGAACTGAGGTGGGAAACCATTCAAGCAAATCTTCCACAGTTGTTCAAGAATCT
TCTAAAGGCACACCTCGGTCTTACTTAGCTTCCAGTCCAAACCCATTCAGCCGTGCAAAT
GCAGCTGAAACCATATCTGCAGCAAGAGCACTTCCATCTGCTTCTCCTACTTCTATCCGA
ACTGGATATATGCCTCGAAAGGCTTCAGTTGGATCTGCTTCTACTCGTCACGTGTTTGGA
TCAAGACTGCAGAGGATAAAGACCACAGTTAATACCATAGGGGCTACTGGGAAGTTGTCA
GCTACTCCTCCTCCATCGGCTCCACCACCTTCTGGATCTGGCACAAGTAAAATAGACAAA
TATGCCCGTATTCTCTTTCCAGTCACATTTGGGGCATTTAACATGGTTTATTGGGTTGTT
TATTTATCTAAGGACACTATGGAGAAATCAGAAAGTCTAATGTAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>554</residue_number>
    <molecular_weight>61622.6</molecular_weight>
    <theoretical_pi>10.02</theoretical_pi>
    <pfams>
      <pfam>
        <name>Neur_chan_LBD</name>
        <pfam_id>PF02931</pfam_id>
      </pfam>
      <pfam>
        <name>Neur_chan_memb</name>
        <pfam_id>PF02932</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>259-280</region>
      <region>285-306</region>
      <region>318-340</region>
      <region>524-543</region>
    </transmembrane_regions>
    <signal_regions>
      <region>1-35</region>
    </signal_regions>
    <protein_sequence>&gt;Gamma-aminobutyric acid receptor subunit alpha-4
MVSAKKVPAIALSAGVSFALLRFLCLAVCLNESPGQNQKEEKLCTENFTRILDSLLDGYD
NRLRPGFGGPVTEVKTDIYVTSFGPVSDVEMEYTMDVFFRQTWIDKRLKYDGPIEILRLN
NMMVTKVWTPDTFFRNGKKSVSHNMTAPNKLFRIMRNGTILYTMRLTISAECPMRLVDFP
MDGHACPLKFGSYAYPKSEMIYTWTKGPEKSVEVPKESSSLVQYDLIGQTVSSETIKSIT
GEYIVMTVYFHLRRKMGYFMIQTYIPCIMTVILSQVSFWINKESVPARTVFGITTVLTMT
TLSISARHSLPKVSYATAMDWFIAVCFAFVFSALIEFAAVNYFTNIQMEKAKRKTSKPPQ
EVPAAPVQREKHPEAPLQNTNANLNMRKRTNALVHSESDVGNRTEVGNHSSKSSTVVQES
SKGTPRSYLASSPNPFSRANAAETISAARALPSASPTSIRTGYMPRKASVGSASTRHVFG
SRLQRIKTTVNTIGATGKLSATPPPSAPPPSGSGTSKIDKYARILFPVTFGAFNMVYWVV
YLSKDTMEKSESLM</protein_sequence>
  </protein_properties>
  <genbank_protein_id>34452723</genbank_protein_id>
  <uniprot_id>P48169</uniprot_id>
  <uniprot_name>GBRA4_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>NM_000809.2</genbank_gene_id>
  <genecard_id>GABRA4</genecard_id>
  <geneatlas_id>GABRA4</geneatlas_id>
  <hgnc_id>HGNC:4078</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Yang W, Drewe JA, Lan NC: Cloning and characterization of the human GABAA receptor alpha 4 subunit: identification of a unique diazepam-insensitive binding site. Eur J Pharmacol. 1995 Nov 30;291(3):319-25.</reference_text>
      <pubmed_id>8719416</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hillier LW, Graves TA, Fulton RS, Fulton LA, Pepin KH, Minx P, Wagner-McPherson C, Layman D, Wylie K, Sekhon M, Becker MC, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Kremitzki C, Oddy L, Du H, Sun H, Bradshaw-Cordum H, Ali J, Carter J, Cordes M, Harris A, Isak A, van Brunt A, Nguyen C, Du F, Courtney L, Kalicki J, Ozersky P, Abbott S, Armstrong J, Belter EA, Caruso L, Cedroni M, Cotton M, Davidson T, Desai A, Elliott G, Erb T, Fronick C, Gaige T, Haakenson W, Haglund K, Holmes A, Harkins R, Kim K, Kruchowski SS, Strong CM, Grewal N, Goyea E, Hou S, Levy A, Martinka S, Mead K, McLellan MD, Meyer R, Randall-Maher J, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Shah N, Swearengen-Shahid S, Snider J, Strong JT, Thompson J, Yoakum M, Leonard S, Pearman C, Trani L, Radionenko M, Waligorski JE, Wang C, Rock SM, Tin-Wollam AM, Maupin R, Latreille P, Wendl MC, Yang SP, Pohl C, Wallis JW, Spieth J, Bieri TA, Berkowicz N, Nelson JO, Osborne J, Ding L, Meyer R, Sabo A, Shotland Y, Sinha P, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Jones TA, She X, Ciccarelli FD, Izaurralde E, Taylor J, Schmutz J, Myers RM, Cox DR, Huang X, McPherson JD, Mardis ER, Clifton SW, Warren WC, Chinwalla AT, Eddy SR, Marra MA, Ovcharenko I, Furey TS, Miller W, Eichler EE, Bork P, Suyama M, Torrents D, Waterston RH, Wilson RK: Generation and annotation of the DNA sequences of human chromosomes 2 and 4. Nature. 2005 Apr 7;434(7034):724-31.</reference_text>
      <pubmed_id>15815621</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>McLean PJ, Farb DH, Russek SJ: Mapping of the alpha 4 subunit gene (GABRA4) to human chromosome 4 defines an alpha 2-alpha 4-beta 1-gamma 1 gene cluster: further evidence that modern GABAA receptor gene clusters are derived from an ancestral cluster. Genomics. 1995 Apr 10;26(3):580-6.</reference_text>
      <pubmed_id>7607683</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tang LY, Deng N, Wang LS, Dai J, Wang ZL, Jiang XS, Li SJ, Li L, Sheng QH, Wu DQ, Li L, Zeng R: Quantitative phosphoproteome profiling of Wnt3a-mediated signaling network: indicating the involvement of ribonucleoside-diphosphate reductase M2 subunit phosphorylation at residue serine 20 in canonical Wnt signal transduction. Mol Cell Proteomics. 2007 Nov;6(11):1952-67. Epub 2007 Aug 12.</reference_text>
      <pubmed_id>17693683</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers.  Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.</reference_text>
      <pubmed_id>16959974</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Lorazepam</name>
        <accession>HMDB14332</accession>
      </metabolite>
      <reference>
        <reference_text>Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4.</reference_text>
        <pubmed_id>20138190</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lorazepam</name>
        <accession>HMDB14332</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lorazepam</name>
        <accession>HMDB14332</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethchlorvynol</name>
        <accession>HMDB14335</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethchlorvynol</name>
        <accession>HMDB14335</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Temazepam</name>
        <accession>HMDB14376</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Temazepam</name>
        <accession>HMDB14376</accession>
      </metabolite>
      <reference>
        <reference_text>Giersch A, Boucart M, Elliott M, Vidailhet P: Atypical behavioural effects of lorazepam: clues to the design of novel therapies? Pharmacol Ther. 2010 Apr;126(1):94-108. Epub 2010 Feb 4.</reference_text>
        <pubmed_id>20138190</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butabarbital</name>
        <accession>HMDB14382</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butalbital</name>
        <accession>HMDB14386</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Talbutal</name>
        <accession>HMDB14451</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentobarbital</name>
        <accession>HMDB14457</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clobazam</name>
        <accession>HMDB14493</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clobazam</name>
        <accession>HMDB14493</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meprobamate</name>
        <accession>HMDB14515</accession>
      </metabolite>
      <reference>
        <reference_text>Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91.</reference_text>
        <pubmed_id>9067327</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meprobamate</name>
        <accession>HMDB14515</accession>
      </metabolite>
      <reference>
        <reference_text>Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. Epub 2009 Feb 24.</reference_text>
        <pubmed_id>19244096</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alpha-hydroxyalprazolam</name>
        <accession>HMDB13943</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Secobarbital</name>
        <accession>HMDB14562</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metharbital</name>
        <accession>HMDB14606</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlordiazepoxide</name>
        <accession>HMDB14618</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlordiazepoxide</name>
        <accession>HMDB14618</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Thiopental</name>
        <accession>HMDB14737</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clorazepate</name>
        <accession>HMDB14766</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clorazepate</name>
        <accession>HMDB14766</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurazepam</name>
        <accession>HMDB14828</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurazepam</name>
        <accession>HMDB14828</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Primidone</name>
        <accession>HMDB14932</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxazepam</name>
        <accession>HMDB14980</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxazepam</name>
        <accession>HMDB14980</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenobarbital</name>
        <accession>HMDB14987</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylphenobarbital</name>
        <accession>HMDB14987</accession>
      </metabolite>
      <reference>
        <reference_text>Olsen RW, Li GD: GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth. 2011 Feb;58(2):206-15. Epub 2010 Dec 31.</reference_text>
        <pubmed_id>21194017</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triazolam</name>
        <accession>HMDB15034</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triazolam</name>
        <accession>HMDB15034</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clonazepam</name>
        <accession>HMDB15201</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clonazepam</name>
        <accession>HMDB15201</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amobarbital</name>
        <accession>HMDB15440</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aprobarbital</name>
        <accession>HMDB15441</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Butethal</name>
        <accession>HMDB15442</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Heptabarbital</name>
        <accession>HMDB15443</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3'-Hydroxyhexobarbital</name>
        <accession>HMDB13940</accession>
      </metabolite>
      <reference>
        <reference_text>Mehta AK, Ticku MK: An update on GABAA receptors.  Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217.</reference_text>
        <pubmed_id>10209232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>Oblak AL, Gibbs TT, Blatt GJ: Reduced GABAA receptors and benzodiazepine binding sites in the posterior cingulate cortex and fusiform gyrus in autism. Brain Res. 2011 Mar 22;1380:218-28. Epub 2010 Sep 19.</reference_text>
        <pubmed_id>20858465</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>You H, Kozuska JL, Paulsen IM, Dunn SM: Benzodiazepine modulation of the rat GABAA receptor alpha4beta3gamma2L subtype expressed in Xenopus oocytes. Neuropharmacology. 2010 Nov;59(6):527-33. Epub 2010 Jul 16.</reference_text>
        <pubmed_id>20638393</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>Skilbeck KJ, O'Reilly JN, Johnston GA, Hinton T: Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):492-8. Epub 2007 Oct       10.</reference_text>
        <pubmed_id>17976880</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromazepam</name>
        <accession>HMDB15511</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrazepam</name>
        <accession>HMDB15534</accession>
      </metabolite>
      <reference>
        <reference_text>Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology.  J Pharmacol Exp Ther. 2002 Jan;300(1):2-8.</reference_text>
        <pubmed_id>11752090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrazepam</name>
        <accession>HMDB15534</accession>
      </metabolite>
      <reference>
        <reference_text>Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.  Acta Neurol Scand. 2008 Aug;118(2):69-86. Epub 2008 Mar 31.</reference_text>
        <pubmed_id>18384456</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
